Author's response to reviews

Title: Subjective Response to Antipsychotic Treatment and Compliance in Schizophrenia. A Naturalistic Study Comparing Olanzapine, Risperidone and Haloperidol (EFESO Study).

Authors:

Ignacio Garcia-Cabeza (igarcia@gio.ingor.upm.es)
Juan Carlos Gomez (gomez_juan-carlos@lilly.com)
Jose A Sacristan (sacristan_jose@lilly.com)
Eric Edgell (edgell_eric@lilly.com)
Manuel Gonzalez de Chavez (MGCHAVEZ@teleline.es)

Version: 2 Date: 18 Dec 2001

Madrid, 14 December 2001
BioMed Central
Psychiatry

Dear Editor,

I send you enclosed the revised version of the manuscript

Title:
SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC TREATMENT AND COMPLIANCE IN SCHIZOPHRENIA. A NATURALISTIC STUDY COMPARING OLANZAPINE, RISPERIDONE AND HALOPERIDOL (EFESO Study).

Authors:

Ignacio Garcia-Cabeza, Juan Carlos Gomez, Jose Antonio Sacristan, Eric Edgell, Manuel Gonzalez de Chavez, for the EFESO Study Group.

In response to the comments from the referee we have made the following changes:

The compliance analysis by EPS category has been deleted (Table VI and wording in the results section).

We have acknowledged that risperidone likelihood to induce EPS is dose-dependent: "Risperidone is known to induce EPS in a dose-dependent fashion and therefore, results might have been different if risperidone had been lower. Nevertheless, risperidone dose in this study is consistent with published reports from clinical practice".

We have acknowledged that the DAI-10 was, to a large extent, designed to detect subjective impact of EPS.

We have included a reference to the publication by Voruganti et al: "There is a recent publication of a
cross-sectional study that reports better subjective response measured with the DAI-30 in patients treated with new antipsychotics compared to conventional antipsychotics, but not difference between different new antipsychotics (risperidone, olanzapine, quetiapine and clozapine)."

Thank you in advance for your attention to our work. With best regards,

Corresponding author:
Juan Carlos Gomez,
Medical Director,
Eli Lilly and Company,
Avenida de la Industria 30,
28108 Alcobendas, Madrid, Spain,
Tel: 34-91-6635097. Fax: 34-91-6635231,
E-mail: gomez_juan-carlos@lilly.com